Adam R. Craig

Insider · Executive Chairman · XFOR

Adam R. Craig files insider transactions with the SEC as an executive chairman of X4 Pharmaceuticals (XFOR). We hold 1 disclosed purchase or sale filed since 30 June 2006, 1 of them in the last 90 days.

Files forXFOR
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure13 August 2026

Positions held

6 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 12 August 2025 — 12 August 2026Executive Chairman · X4 Pharmaceuticals (XFOR)6 Form 4 lines · source: SEC Form 4
Filed 20 March 2017 — 26 June 2023President and CEO · Cti Biopharma (CTIC)82 Form 4 lines · source: SEC Form 4
Filed 29 September 2017 — 16 May 2019President and CEO · Cti Biopharma (ctic)4 Form 4 lines · source: SEC Form 4
Filed 29 February 2012 — 27 February 2015EVP, Development & CMO · Sunesis Pharmaceuticals (SNSS)8 Form 4 lines · source: SEC Form 4
Filed 29 June 2006 — 10 July 2007VP and Chief Medical Officer · Innovive Pharmaceuticals (IVPH.OB)7 Form 4 lines · source: SEC Form 4
Filed 29 June 2006 — 8 August 2006VP and Chief Medical Officer · Innovive Pharmaceuticals (NONE)2 Form 4 lines · source: SEC Form 4

Everything they disclosed

109 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 47,436 shares of X4 PharmaceuticalsSEC Form 413 August 2026Common Stock · traded 12 August 2026 · filed 13 August 2026
was granted 2,329,154 shares of X4 Pharmaceuticals (a derivative holding)SEC Form 431 October 2025Stock Option (right to buy) · traded 29 October 2025 · filed 31 October 2025
▲ bought on the open market 86,206 shares of X4 PharmaceuticalsSEC Form 427 October 2025Common Stock · traded 23 October 2025 · filed 27 October 2025
was granted 1,609,873 shares of X4 Pharmaceuticals (a derivative holding)SEC Form 414 August 2025Stock Option (right to buy) · traded 12 August 2025 · filed 14 August 2025
was granted 529,201 shares of X4 Pharmaceuticals (a derivative holding)SEC Form 414 August 2025Stock Option (right to buy) · traded 14 August 2025 · filed 14 August 2025
was granted 289,881 shares of X4 PharmaceuticalsSEC Form 414 August 2025Common Stock · traded 14 August 2025 · filed 14 August 2025
returned to the issuer 1,200,000 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
returned to the issuer 450,000 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
returned to the issuer 475,000 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
returned to the issuer 600,000 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
returned to the issuer 470,054 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
returned to the issuer 2,320,000 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
returned to the issuer 800,000 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
returned to the issuer 1,115,000 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
returned to the issuer 900,000 shares of Cti Biopharma (a derivative holding)SEC Form 426 June 2023Stock Option (Right to Buy) · traded 26 June 2023 · filed 26 June 2023
disposed of in a tender offer 31,470 shares of Cti BiopharmaSEC Form 426 June 2023Common Stock · traded 26 June 2023 · filed 26 June 2023
was granted 900,000 shares of Cti Biopharma (a derivative holding)SEC Form 416 March 2023Stock Option (right to buy) · traded 14 March 2023 · filed 16 March 2023
exercised options over 83,200 shares of Cti Biopharma (a derivative holding)SEC Form 426 January 2023Non-Qualified Stock Option (right to buy) · traded 24 January 2023 · filed 26 January 2023
exercised options over 2,117 shares of Cti Biopharma (a derivative holding)SEC Form 426 January 2023Non-Qualified Stock Option (right to buy) · traded 24 January 2023 · filed 26 January 2023
exercised options over 83,200 shares of Cti BiopharmaSEC Form 426 January 2023common stock · traded 24 January 2023 · filed 26 January 2023
▼ sold on the open market 83,200 shares of Cti BiopharmaSEC Form 426 January 2023common stock · traded 24 January 2023 · filed 26 January 2023
exercised options over 2,117 shares of Cti BiopharmaSEC Form 426 January 2023common stock · traded 24 January 2023 · filed 26 January 2023
▼ sold on the open market 2,117 shares of Cti BiopharmaSEC Form 426 January 2023common stock · traded 24 January 2023 · filed 26 January 2023
exercised options over 13,800 shares of Cti Biopharma (a derivative holding)SEC Form 43 January 2023Non-Qualified Stock Option (right to buy) · traded 29 December 2022 · filed 3 January 2023
exercised options over 12,000 shares of Cti Biopharma (a derivative holding)SEC Form 43 January 2023Non-Qualified Stock Option (right to buy) · traded 30 December 2022 · filed 3 January 2023
exercised options over 700 shares of Cti Biopharma (a derivative holding)SEC Form 43 January 2023Non-Qualified Stock Option (right to buy) · traded 30 December 2022 · filed 3 January 2023
exercised options over 4,400 shares of Cti Biopharma (a derivative holding)SEC Form 43 January 2023Non-Qualified Stock Option (right to buy) · traded 30 December 2022 · filed 3 January 2023
exercised options over 84,683 shares of Cti Biopharma (a derivative holding)SEC Form 43 January 2023Non-Qualified Stock Option (right to buy) · traded 3 January 2023 · filed 3 January 2023
exercised options over 13,800 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 29 December 2022 · filed 3 January 2023
▼ sold on the open market 13,800 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 29 December 2022 · filed 3 January 2023
was granted 1,579 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 30 December 2022 · filed 3 January 2023
exercised options over 12,000 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 30 December 2022 · filed 3 January 2023
▼ sold on the open market 12,000 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 30 December 2022 · filed 3 January 2023
exercised options over 700 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 30 December 2022 · filed 3 January 2023
▼ sold on the open market 700 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 30 December 2022 · filed 3 January 2023
exercised options over 4,400 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 30 December 2022 · filed 3 January 2023
▼ sold on the open market 4,400 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 30 December 2022 · filed 3 January 2023
exercised options over 84,683 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 3 January 2023 · filed 3 January 2023
▼ sold on the open market 84,683 shares of Cti BiopharmaSEC Form 43 January 2023common stock · traded 3 January 2023 · filed 3 January 2023
exercised options over 53,996 shares of Cti Biopharma (a derivative holding)SEC Form 414 November 2022Non-Qualified Stock Option (right to buy) · traded 9 November 2022 · filed 14 November 2022
exercised options over 188,304 shares of Cti Biopharma (a derivative holding)SEC Form 414 November 2022Non-Qualified Stock Option (right to buy) · traded 10 November 2022 · filed 14 November 2022
exercised options over 53,996 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 46,100 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 7,596 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 9 November 2022 · filed 14 November 2022
▼ sold on the open market 300 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 9 November 2022 · filed 14 November 2022
exercised options over 188,304 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 10 November 2022 · filed 14 November 2022
▼ sold on the open market 136,408 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 10 November 2022 · filed 14 November 2022
▼ sold on the open market 200 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 10 November 2022 · filed 14 November 2022
▼ sold on the open market 26,700 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 10 November 2022 · filed 14 November 2022
▼ sold on the open market 100 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 10 November 2022 · filed 14 November 2022
▼ sold on the open market 16,396 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 10 November 2022 · filed 14 November 2022
▼ sold on the open market 5,800 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 10 November 2022 · filed 14 November 2022
▼ sold on the open market 2,700 shares of Cti BiopharmaSEC Form 414 November 2022common stock · traded 10 November 2022 · filed 14 November 2022
exercised options over 242,300 shares of Cti Biopharma (a derivative holding)SEC Form 414 September 2022Non-Qualified Stock Option (right to buy) · traded 12 September 2022 · filed 14 September 2022
exercised options over 242,300 shares of Cti BiopharmaSEC Form 414 September 2022Common Stock · traded 12 September 2022 · filed 14 September 2022
▼ sold on the open market 242,300 shares of Cti BiopharmaSEC Form 414 September 2022Common Stock · traded 12 September 2022 · filed 14 September 2022
▲ bought on the open market 5,000 shares of Cti BiopharmaSEC Form 416 August 2022common stock · traded 16 August 2022 · filed 16 August 2022
exercised options over 27,000 shares of Cti Biopharma (a derivative holding)SEC Form 46 July 2022Non-Qualified Stock Option (right to buy) · traded 1 July 2022 · filed 6 July 2022
exercised options over 27,000 shares of Cti Biopharma (a derivative holding)SEC Form 46 July 2022Non-Qualified Stock Option (right to buy) · traded 5 July 2022 · filed 6 July 2022
exercised options over 18,223 shares of Cti Biopharma (a derivative holding)SEC Form 46 July 2022Non-Qualified Stock Option (right to buy) · traded 6 July 2022 · filed 6 July 2022
was granted 6,183 shares of Cti BiopharmaSEC Form 46 July 2022common stock · traded 30 June 2022 · filed 6 July 2022
exercised options over 27,000 shares of Cti BiopharmaSEC Form 46 July 2022common stock · traded 1 July 2022 · filed 6 July 2022
▼ sold on the open market 27,000 shares of Cti BiopharmaSEC Form 46 July 2022common stock · traded 1 July 2022 · filed 6 July 2022
exercised options over 27,000 shares of Cti BiopharmaSEC Form 46 July 2022common stock · traded 5 July 2022 · filed 6 July 2022
▼ sold on the open market 27,000 shares of Cti BiopharmaSEC Form 46 July 2022common stock · traded 5 July 2022 · filed 6 July 2022
exercised options over 18,223 shares of Cti BiopharmaSEC Form 46 July 2022common stock · traded 6 July 2022 · filed 6 July 2022
▼ sold on the open market 18,223 shares of Cti BiopharmaSEC Form 46 July 2022common stock · traded 6 July 2022 · filed 6 July 2022
exercised options over 27,000 shares of Cti Biopharma (a derivative holding)SEC Form 43 June 2022common stock · traded 1 June 2022 · filed 3 June 2022
exercised options over 27,000 shares of Cti Biopharma (a derivative holding)SEC Form 43 June 2022common stock · traded 2 June 2022 · filed 3 June 2022
exercised options over 18,223 shares of Cti Biopharma (a derivative holding)SEC Form 43 June 2022common stock · traded 3 June 2022 · filed 3 June 2022
exercised options over 27,000 shares of Cti BiopharmaSEC Form 43 June 2022common stock · traded 1 June 2022 · filed 3 June 2022
▼ sold on the open market 27,000 shares of Cti BiopharmaSEC Form 43 June 2022common stock · traded 1 June 2022 · filed 3 June 2022
exercised options over 27,000 shares of Cti BiopharmaSEC Form 43 June 2022common stock · traded 2 June 2022 · filed 3 June 2022
▼ sold on the open market 27,000 shares of Cti BiopharmaSEC Form 43 June 2022common stock · traded 2 June 2022 · filed 3 June 2022
exercised options over 18,223 shares of Cti BiopharmaSEC Form 43 June 2022common stock · traded 3 June 2022 · filed 3 June 2022
▼ sold on the open market 18,223 shares of Cti BiopharmaSEC Form 43 June 2022common stock · traded 3 June 2022 · filed 3 June 2022
exercised options over 27,000 shares of Cti Biopharma (a derivative holding)SEC Form 43 June 2022Non-Qualified Stock Option (right to buy) · traded 1 June 2022 · filed 3 June 2022
exercised options over 27,000 shares of Cti Biopharma (a derivative holding)SEC Form 43 June 2022Non-Qualified Stock Option (right to buy) · traded 2 June 2022 · filed 3 June 2022
exercised options over 18,223 shares of Cti Biopharma (a derivative holding)SEC Form 43 June 2022Non-Qualified Stock Option (right to buy) · traded 3 June 2022 · filed 3 June 2022
was granted 1,115,000 shares of Cti Biopharma (a derivative holding)SEC Form 411 March 2022Stock Option (right to buy) · traded 9 March 2022 · filed 11 March 2022
was granted 3,178 shares of Cti BiopharmaSEC Form 411 March 2022Common Stock · traded 31 December 2021 · filed 11 March 2022
was granted 5,000 shares of Cti BiopharmaSEC Form 42 December 2021common stock · traded 30 June 2021 · filed 2 December 2021
▲ bought on the open market 1,322 shares of Cti BiopharmaSEC Form 42 December 2021common stock · traded 2 December 2021 · filed 2 December 2021
▲ bought on the open market 2,178 shares of Cti BiopharmaSEC Form 42 December 2021common stock · traded 2 December 2021 · filed 2 December 2021
was granted 5,000 shares of Cti BiopharmaSEC Form 412 March 2021Common Stock · traded 1 July 2020 · filed 12 March 2021
was granted 800,000 shares of Cti Biopharma (a derivative holding)SEC Form 412 March 2021Stock Option (right to buy) · traded 10 March 2021 · filed 12 March 2021
was granted 2,320,000 shares of Cti Biopharma (a derivative holding)SEC Form 413 March 2020Non-qualified Stock Option · traded 11 March 2020 · filed 13 March 2020
was granted 1,300,000 shares of Cti Biopharma (a derivative holding)SEC Form 420 May 2019Non-Qualified Stock Option (right to buy) · traded 16 May 2019 · filed 20 May 2019
was granted 600,000 shares of Cti Biopharma (a derivative holding)SEC Form 420 September 2018Non-Qualified Stock Option (right to buy) · traded 18 September 2018 · filed 20 September 2018
was granted 475,000 shares of Cti Biopharma (a derivative holding)SEC Form 417 May 2018Non-Qualified Stock Option (right to buy) · traded 16 May 2018 · filed 17 May 2018
was granted 450,000 shares of Cti Biopharma (a derivative holding)SEC Form 43 October 2017Non-Qualified Stock Option (right to buy) · traded 29 September 2017 · filed 3 October 2017
was granted 1,200,000 shares of Cti Biopharma (a derivative holding)SEC Form 421 March 2017Stock Option (Right to Buy) · traded 20 March 2017 · filed 21 March 2017
was granted 19,031 shares of Sunesis PharmaceuticalsSEC Form 42 March 2015Common Stock · traded 27 February 2015 · filed 2 March 2015
had shares withheld for tax on 8,302 shares of Sunesis PharmaceuticalsSEC Form 42 March 2015Common Stock · traded 27 February 2015 · filed 2 March 2015
was granted 140,000 shares of Sunesis Pharmaceuticals (a derivative holding)SEC Form 43 November 2014Stock Option (Right to Buy) · traded 31 October 2014 · filed 3 November 2014
▼ sold on the open market 2,554 shares of Sunesis PharmaceuticalsSEC Form 429 August 2014Common Stock · traded 27 August 2014 · filed 29 August 2014
was granted 140,000 shares of Sunesis Pharmaceuticals (a derivative holding)SEC Form 44 March 2014Stock Option Right to Buy · traded 28 February 2014 · filed 4 March 2014
was granted 7,662 shares of Sunesis PharmaceuticalsSEC Form 41 March 2013Common Stock · traded 28 February 2013 · filed 1 March 2013
was granted 125,000 shares of Sunesis Pharmaceuticals (a derivative holding)SEC Form 41 March 2013Stock Option (Right to Buy) · traded 28 February 2013 · filed 1 March 2013
was granted 600,000 shares of Sunesis Pharmaceuticals (a derivative holding)SEC Form 42 March 2012Stock Option (Right to Buy) · traded 29 February 2012 · filed 2 March 2012
converted 17,120 shares of Innovive Pharmaceuticals (a derivative holding)SEC Form 423 July 2007Series A Convertible Preferred Stock · traded 29 June 2006 · filed 23 July 2007
▲ bought on the open market 1,833 shares of Innovive Pharmaceuticals (a derivative holding)SEC Form 423 July 2007Warrant (Right to Buy) · traded 29 June 2006 · filed 23 July 2007
converted 17,120 shares of Innovive Pharmaceuticals (a derivative holding)SEC Form 423 July 2007Series A Convertible Preferred Stock · traded 10 August 2006 · filed 23 July 2007
was granted 70,000 shares of Innovive Pharmaceuticals (a derivative holding)SEC Form 423 July 2007Stock Option (Right to Buy) · traded 8 August 2006 · filed 23 July 2007
converted 17,120 shares of Innovive PharmaceuticalsSEC Form 423 July 2007Common Stock · traded 10 August 2006 · filed 23 July 2007
was granted 37,500 shares of Innovive Pharmaceuticals (a derivative holding)SEC Form 423 July 2007Stock Option (Right to Buy) · traded 10 July 2007 · filed 23 July 2007
was granted 37,500 shares of Innovive Pharmaceuticals (a derivative holding)SEC Form 423 July 2007Stock Option (Right to Buy) · traded 10 July 2007 · filed 23 July 2007
was granted 70,000 shares of Innovive Pharmaceuticals (a derivative holding)SEC Form 410 August 2006Stock Option (Right to Buy) · traded 8 August 2006 · filed 10 August 2006
converted 17,120 shares of Innovive Pharmaceuticals (a derivative holding)SEC Form 430 June 2006Series A Convertible Preferred Stock · traded 29 June 2006 · filed 30 June 2006

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.